Hardman Johnston Global Advisors LLC Sells 23,450 Shares of IQVIA Holdings Inc. $IQV

Hardman Johnston Global Advisors LLC lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 16.4% in the third quarter, Holdings Channel.com reports. The firm owned 119,776 shares of the medical research company’s stock after selling 23,450 shares during the period. IQVIA comprises about 1.1% of Hardman Johnston Global Advisors LLC’s investment portfolio, making the stock its 29th biggest position. Hardman Johnston Global Advisors LLC’s holdings in IQVIA were worth $22,750,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Tokio Marine Asset Management Co. Ltd. boosted its holdings in IQVIA by 4.6% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 6,302 shares of the medical research company’s stock worth $1,197,000 after buying an additional 280 shares during the period. First Horizon Corp purchased a new stake in shares of IQVIA during the third quarter worth $653,000. MGO One Seven LLC boosted its holdings in shares of IQVIA by 240.2% in the third quarter. MGO One Seven LLC now owns 11,606 shares of the medical research company’s stock worth $2,204,000 after acquiring an additional 8,194 shares during the period. Citizens Financial Group Inc. RI grew its position in shares of IQVIA by 11.4% in the third quarter. Citizens Financial Group Inc. RI now owns 2,561 shares of the medical research company’s stock valued at $487,000 after purchasing an additional 263 shares in the last quarter. Finally, Cannon Advisors Inc. bought a new stake in shares of IQVIA during the 3rd quarter valued at $190,000. Institutional investors own 89.62% of the company’s stock.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Down 0.2%

Shares of NYSE IQV opened at $242.70 on Monday. The stock has a market capitalization of $41.33 billion, a P/E ratio of 33.29, a PEG ratio of 2.47 and a beta of 1.36. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.05. The firm’s 50 day simple moving average is $224.37 and its two-hundred day simple moving average is $200.77. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Evercore ISI lifted their target price on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. Mizuho set a $266.00 target price on shares of IQVIA in a research note on Friday. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, December 20th. JPMorgan Chase & Co. increased their price objective on IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Finally, Baird R W upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $249.19.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.